Serum Values of Alkaline Phosphatase and Lactate Dehydrogenase in Osteosarcoma

Zumárraga, Juan Pablo; Baptista, André Mathias; Rosa, Luis Pablo de La; Caiero, Marcelo Tadeu; Camargo, Olavo Pires de

doi:10.1590/1413-785220162403157033

Cited by 16 publications

(16 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Osteosarcoma (OS) is the most common primary bone malignancy and is diagnosed through radiological investigations and standard tissue biopsy. Some molecules present in the peripheral blood, such as alkaline phosphatase (AKP) and lactate dehydrogenase (LDH), have been proposed to serve as biomarkers for the diagnosis of OS, but they are not specific for OS and remain on debate with regard to the accuracy and reliability [1,2]. Recently, serum miRNAs (such as miR-124 [3]) and metabolomics (such as fibrinogen, vascular endothelial growth factor, and basic fibroblast growth factor [4]) were also reported to have diagnostic and prognostic value for OS.…”

Section: Introductionmentioning

confidence: 99%

EFEMP1 as a Potential Biomarker for Diagnosis and Prognosis of Osteosarcoma

Wang

Kang

Lian

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Osteosarcoma (OS) is the most common primary bone malignancy. Our previous study revealed an association between the level of epidermal growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1) and the invasion, metastasis, and poor prognosis of OS. However, the exact correlation between the serum EFEMP1 level and OS diagnosis and progression was unclear. This study is aimed at determining the value of the serum EFEMP1 level in the diagnosis and prognosis of OS. Fifty-one consecutive OS patients were prospectively registered in this study. The serum EFEMP1 levels were measured using ELISA at diagnosis, after neoadjuvant chemotherapy, and before and after surgical treatment. Sixty-nine healthy subjects in the control group, nine patients with chondrosarcoma, and 12 patients with giant cell tumor of the bone were also enrolled in this study. Surgical orthotopic implantation was used to generate a mouse OS model, and the correlation between the circulating EFEMP1 levels and tumor progression was examined. Then, OS patients had significantly higher mean serum EFEMP1 levels (7.61 ng/ml) than the control subjects (1.47 ng/ml). The serum EFEMP1 levels were correlated with the Enneking staging system (r=0.32, P=0.021) and lung metastasis (r=0.50, P<0.001). There was also a correlation between the serum EFEMP1 level and EFEMP1 expression in the respective OS samples (r=0.49, P<0.001). Additionally, patients with either chondrosarcoma or giant cell tumor of the bone had significantly higher serum EFEMP1 levels than OS patients. Surgical and chemotherapeutic treatment led to an increase in the serum EFEMP1 levels. Then, the destruction of bone tissues might be one of the factors about the EFEMP1 levels. In the mouse OS model, the serum EFEMP1 level was correlated with tumor progression. Our results suggested that serum EFEMP1 levels might be used to distinguish OS patients from healthy controls and as an indicator for OS lung metastasis. Serum EFEMP1 levels could serve as a new and assisted biomarker for the auxiliary diagnosis and prognosis of OS.

show abstract

Section: Introductionmentioning

confidence: 99%

EFEMP1 as a Potential Biomarker for Diagnosis and Prognosis of Osteosarcoma

Wang

Kang

Lian

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…In one such study, serum levels of ALP and LDH were analyzed pre- and post-chemotherapy. Both enzymes were found to be higher pre-chemotherapy compared to post-chemotherapy [ 84 ]. No correlation was observed between these enzymes and the percentage of tumor necrosis in OS patients.…”

Section: Enzyme Markersmentioning

confidence: 99%

Identification of Prognostic and Predictive Osteosarcoma Biomarkers

et al. 2019

View full text Add to dashboard Cite

Both adolescents and children suffer from osteosarcoma, localized in the metaphysis of the long bones. This is the most common primary high-grade bone tumor in this patient group. Early tumor detection is the key to ensuring effective treatment. Improved osteosarcoma outcomes in clinical trials have been contingent on biomarker discovery and an evolving understanding of molecules and their complex interactions. In this review, we present a short overview of biomarkers for osteosarcoma, and highlight advances in osteosarcoma-related biomarker research. Many studies show that several biomarkers undergo critical changes with osteosarcoma progression. Growing knowledge about osteosarcoma-related markers is expected to positively impact the development of therapeutics for osteosarcoma, and ultimately of clinical care. It has also become important to develop new biomarkers, which can identify vulnerable patients who should be treated with more intensive and aggressive therapy after diagnosis.

show abstract

“…The need for OS biomarkers is reflected in a large yet inconclusive literature. Early studies focusing on bone markers such as alkaline phosphatase showed highly variable increases in OS patients 6 . Later proteomic studies revealed two as-yet uncharacterized OS-associated proteins 7 whereas studies of miRNAs showed variable results 8 – 10 .…”

Section: Introductionmentioning

confidence: 99%

Extracellular vesicle-associated repetitive element DNAs as candidate osteosarcoma biomarkers

Cambier

Stachelek

Triska

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Osteosarcoma (OS) is the most common malignant bone tumor in children and young adults. Despite that high-risk factors have been identified, no test for early detection is available. This study aimed to identify circulating nucleic acid sequences associated with serum extracellular vesicle (EV) preparations at the time of OS diagnosis, as a step towards an OS early detection assay. Sequencing of small nucleic acids extracted from serum EV preparations revealed increased representation of diverse repetitive element sequences in OS patient versus control sera. Analysis of a validation cohort using qPCR of PEG-precipitated EV preparations revealed the over-representation of HSATI, HSATII, LINE1-P1, and Charlie 3 at the DNA but not RNA level, with receiver operating characteristic (ROC) area under the curve (AUC) ≥ 0.90. HSATI and HSATII DNAs co-purified with EVs prepared by precipitation and size exclusion chromatography but not by exosome immunocapture, indicative of packaging in a non-exosomal complex. The consistent over-representation of EV-associated repetitive element DNA sequences suggests their potential utility as biomarkers for OS and perhaps other cancers.

show abstract

Serum Values of Alkaline Phosphatase and Lactate Dehydrogenase in Osteosarcoma

Cited by 16 publications

References 10 publications

EFEMP1 as a Potential Biomarker for Diagnosis and Prognosis of Osteosarcoma

EFEMP1 as a Potential Biomarker for Diagnosis and Prognosis of Osteosarcoma

Identification of Prognostic and Predictive Osteosarcoma Biomarkers

Extracellular vesicle-associated repetitive element DNAs as candidate osteosarcoma biomarkers

Contact Info

Product

Resources

About